(Q41471081)

English

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

scientific article published on 12 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 October 2017

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial (English)

1 reference

Europe PubMed Central

1 October 2017

multivariate statistics

1 reference

based on heuristic

inferred from title

Eva Hellström-Lindberg

7

object named as

Eva Hellström-Lindberg

0 references

2

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

1 October 2017

author name string

Steven D Gore

1

1 reference

Europe PubMed Central

1 October 2017

Valeria Santini

3

1 reference

Europe PubMed Central

1 October 2017

John M Bennett

4

1 reference

Europe PubMed Central

1 October 2017

Lewis R Silverman

5

1 reference

Europe PubMed Central

1 October 2017

John F Seymour

6

1 reference

Europe PubMed Central

1 October 2017

Eva Hellström-Lindberg

7

1 reference

Europe PubMed Central

1 October 2017

Arlene S Swern

8

1 reference

Europe PubMed Central

1 October 2017

Charles L Beach

9

1 reference

Europe PubMed Central

1 October 2017

Alan F List

10

1 reference

Europe PubMed Central

1 October 2017

publication date

12 April 2013

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

98

1 reference

Europe PubMed Central

1 October 2017

7

1 reference

Europe PubMed Central

1 October 2017

1067-1072

1 reference

Europe PubMed Central

1 October 2017

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Management of patients with higher risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

DNA methylation and gene expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696610

11 June 2018

Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of chemotherapy on acute leukemia in the human

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

1 reference

https://pubmed.ncbi.nlm.nih.gov/23585522

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2012.074831

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41471081&oldid=1922043574"